Sunday (July 7, 2024)
| 15:00 | Registration |
| 17:30 | Opening Ceremony (Room A) Welcome Remarks Xinxin Ding |
| 17:45 – 18:10 | Opening keynote presentation Bettie Sue Masters Duke University, USA A Sojourn Down MDO Memory Lane |
| 18:10 – 18:35 | Opening Symposium In silico and PBPK(D) modeling of drug metabolism Amin Rostami-Hodjegan |
| 18:35 – 19:25 | Opening Symposium In vitro and in silico systems for prediction of drug metabolism and toxicity/ In vitro to in vivo extrapolation (IVIVE) in drug development Matthew A. Cerny - A Comparison of In Vitro and In Vivo Metabolite Profiles – How Predictive are our In Vitro Assays? Carl Petersson - Addressing the challenge of low clearance drug candidates; solutions for the extrapolation from in vitro systems and reaction phenotyping. |
| 19:30 | Welcome drink |
Monday (July 8, 2024)
Plenary lecture (Room A) F. Peter Guengerich | |
Concurrent Symposium 1 (Room A) Novel structural insights and functions of cytochromes P450 Chairs: John C. Hackett - Cytochrome P450 19A1 dynamics and ligand recognition in membranes Stephen Bell - Structural insights into cytochrome P450 enzymes from in crystallo reactions and variable-temperature X-ray crystallography Thomas Pochapsky, Kurt Harris, Nathan Wong, Liam Flynn, Alaina M. Richard, | Concurrent Symposium 2 (Room B) Transcriptional and signaling-based regulation of drug metabolism Chairs: Taoseng Chen - Selective modulation of the promiscuous and dynamic PXR and CYP3A4/5 William Bourguet - Structural insights into ligand binding affinity, specificity and promiscuity in the aryl hydrocarbon receptor Thales Kronenberger - Computational study of conformational changes in nuclear receptors upon ligand binding Jinjing Chen - Hammerhead-type FXR agonists induce an enhancer RNA Fincor: Friend or Foe in metabolic liver disease? (shorter talk) |
| 10:30 - 11:00 Coffee break (30 min) | |
Concurrent Symposium 3 (Room A) Mechanisms and dynamics of P450 and other xenobiotic-metabolizing enzymes Chairs: J. N. Lampe - Molecular dynamics simulations reveal a conserved role for the F/G loop domain in cytochrome P450 CYP3A family multiple ligand binding Emre M. Isin - Unusual Biotransformation Reactions: Expecting the Unexpected James De Voss - Mechanism of P450 catalysed dehydrogenation in the model bacterial P450 CYP199A4 Rebecca C. Wade - Multiscale molecular dynamics simulations to investigate how cytochrome P450 conformational plasticity affects its interactions and function | Concurrent Symposium 4 (Room B) Nuclear Xenobiotic Receptors: PXR and CAR in metabolism and diseases Chairs: Jukka Hakkola - PXR activation-induced effects on metabolic health Petr Pavek - Novel PXR/CAR ligands as an intervention in metabolic diseases Oliver Burk - PXR-dependent modulation of hepatic sphingolipid and phospholipid metabolism Itsuki Yokoseki - BRD9, a chromatin remodeling factor, negatively regulates PPARα-mediated transcription of CPT1A to attenuated lipid metabolism |
12:20 - 13:30 13:30 - 14:30 | |
Concurrent Symposium 5 (Room A) CYPs in endogenous metabolism of lipids and steroids Chairs: Irina Pikuleva - CYP46A1 in the Brain: It is Not Just Cholesterol Elimination Amit V. Pandey - Regulation of Steroid Metabolism by Human Genetic Variations in the Redox Partners of Cytochrome P450 proteins Richard J. Auchus - Why is P450 11B2 an aldosterone synthase and P450 11B1 is not? | Concurrent Symposium 6 (Room B) Drug metabolizing enzymes, transporters, and nuclear receptors as therapeutic targets Chairs: Hongbing Wang - Activation of CAR and Nrf2 in cyclophosphamide- and doxorubicin-based chemotherapy Huichang Bi - The novel role of PXR in liver diseases and beyond Kouichi Yoshinari - Cytochrome P450 inhibition, AHR activation, and liver injury |
15:50 - 16:20 16:20 - 16:40 | |
Concurrent Symposium 7 (Room A) Structure and functions of non-cytochrome P450 enzymes and phase II conjugation enzymes in drug metabolism Chairs: Tatsuki Fukami - Novel characteristics of non-P450 oxidases unraveled from functional analyses Wen Xie - Sulfation in Drug-induced Liver Injury, the expected and unexpected Sheila J. Sadeghi - Flavin-containing monooxygenases: polymorphic variants and their effect on drug metabolism | Concurrent Symposium 8 (Room B) Importance of ncRNAs and lncRNAs in metabolism regulation and liver diseases Chairs: Baitang Ning - The importance of ncRNA and lncRNA in the regulation of metabolism and liver toxicity Shogo Takahashi - The Hidden Regulators: Unveiling the Roles of Two CAR-Regulated lncRNAs in Liver Physiology Using Mouse Knockout Models |
| 20:00 - 22:00 Panoramic Vltava River Cruise with Conference Dinner (not included in the reg. fee) | |
Tuesday (July 9, 2024)
| Plenary lecture (Room A) 8:30 - 9:00 | |
| Magnus Ingelman-Sundberg Department of Physiology and Pharmacology, Karolinska Institutet, Sweden Enhancing Drug - Development Through Innovative 3D Liver Models | |
Concurrent Symposium 9 (Room A) Pharmacogenomics of drug-metabolizing enzymes: clinical relevance and ethnic diversity Chairs: Todd C. Skaar - Discovery of rare ancestry-enriched variants that impact drug metabolism. Rachel F. Tyndale - Big data to investigate the role of polygenic, structurally variable CYP2A6 in disease Matthias Schwab - Innovation in cancer pharmacotherapy through integrative consideration of pharmacogenomics profiles Christopher A. Reilly, Marysol Almestica-Roberts, and Flory L. Nkoy. | Concurrent Symposium 10 (Room B) Novel animal models to predict drug metabolism and toxicity Chairs: Hiroshi Yamazaki - Pharmacokinetic modeling for drugs using inactivated-P450 human hepatocytes after transplantation into immunodeficient mice José E. Manautou - Deciphering the impact of hepatic Multidrug resistance protein 4 (Mrp4) in liver steatosis and metabolic syndrome pathogenesis Mario Mezler - Analysis of the bile acid composition in a fibroblast growth factor 19-expressing liver-humanized mouse model and its use for CYP3A4-mediated drug-drug interaction studies Grace Guo - Generation of Low-bile Acid Mouse Model to Decipher Roles of Individual Bile Acids in MASH Development (a shorter talk) |
| 10:30 - 11:00 Coffee break (30 min) | |
Concurrent Symposium 11 (Room A) Biomarkers for prediction of drug metabolism and toxicity Chairs: Ann Daly - Pharmacogenomics of drug-induced liver injury-metabolic and immunogenetic biomarkers Christopher Goldring - Biomarkers for drug-induced liver injury and the TransBioLine study Mikko Niemi - Circulating biomarkers for drug transporters | Concurrent Symposium 12 (Room B) 3D experimental models and organ-on-chips in drug metabolism Chairs: Volker M. Lauschke - Organotypic and microphysiological primary human tissue models for translational pharmacology Jonathan Sexton - Personalized Liver Injury Risk Prediction: Patient-Derived Organoids on Chip Masaru Koido - How can we translate findings from human genetic association studies? Jasleen K. Sodhi - Hepatic 3D Liver Models and IVIVE |
12:30 - 13:30 13:30 - 14:30 | |
Concurrent Symposium 13 (Room A) Inflammatory regulation of cytochrome P450 enzymes and COVID-19 Chairs: Kerry B. Goralski - COVID-19 and CYP3A4 drug metabolism interactions: A review of the evidence Tore B. Stage - Translational aspects of drug metabolism during inflammation from clinical studies and 3D primary human hepatocytes Gülsah Gabriel - Respiratory virus infection mediated dysregulation of sex hormone metabolism | Concurrent Symposium 14 (Room B) Omics and single-cell-based technologies in the study of drug metabolism Chairs: Albert Braeuning - The use of proteomic approaches to analyze in vivo effects of phenobarbital in mice with humanized livers Damjana Rozman - Targeted omics for innovative decision support systems: examples of COVID-19 and liver cancer Celia P. Martinez-Jimenez - Unraveling Hepatocyte Heterogeneity: Implications for Drug Metabolism and Toxicity Under Metabolic Stress |
15:50 - 16:20 16:20 - 16:40 Commercial presentations K. Yildirim - Empowering Microbiome-Drug Interaction Research: Innovative Tools from Promega R. Xinxin Ding - Publishing your work in ASPET journals. | |
Concurrent Symposium 15 (Room A) Interactions of microbiome on drug metabolism Chairs: Pavel Anzenbacher - Drug Metabolism and Gut Microbiome Hyunyoung (Young) Jeong - Modulation of Drug-induced Hepatotoxicity by Gut Microbial Metabolite Sridhar Mani - Intestinal Microbial metabolites, Nuclear Receptors, and Microbial Metabolite Mimicry: An Update | Concurrent Symposium 16 (Room B) Oligonucleotide and peptide ADME Chairs: Hongbin Yu - Perspectives on ADME of therapeutic proteins Aiming Yu - ADME of therapeutic RNAs Sherouk Tawfik - Triple E challenges for better efficacy of siRNA therapeutics: targeted endocytosis, endosomal escape, and exocytosis |
19:00 | |
Wednesday (July 10, 2024)
Plenary lecture (Room A) Emily E. Scott, Ph.D. | |
Concurrent Symposium 17 (Room A) Intestinal and extrahepatic metabolizing enzymes in bioavailability and disposition Chairs: Xinxin Ding - Dissecting hepatic and extrahepatic contributions to xenobiotic metabolism using transgenic mouse models Stefan Oswald - Intra-subject analysis of gene expression and protein abundance of major and minor drug metabolizing enzymes along the healthy human intestine Joan Z. Zuo - Intestinal carboxylesterase mediated activation of irinotecan and its impact on herb-drug interactions Bhagavatula Moorthy - Attenuation of polycyclic aromatic hydrocarbon (PAH)-induced carcinogenesis by omega 3-fatty acids in vivo (shorter talk) | Concurrent Symposium 18 (Room B) Drug transporters and their impact on drug metabolism and disposition Chairs: Matus Sotak - Circadian regulation of transporter expression: Implications for drug disposition and translational challenges Dirk Theile - The unequal perpetrator effects of rifampicin vs. rifabutin on P-glycoprotein and substrate drugs pharmacokinetics Jean Terrier - Drug transporters and their impact on the pharmacokinetics of direct oral anticoagulants using PK modelling. Sibylle Neuhoff/Matthew D. Harwood - PBPK modeling of endogenous biomarker to assess hepatic and renal transporter-mediated DDIs in healthy and disease |
10:30 - 11:00 11:00 - 12:00 12:00 12:30 - 13:30 Optional Visit to Prague Castle (not incl. in the registration fee) | |
